<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               CLINICAL STUDIES<BR>               <BR>                  Adjuvant Treatment in Early Breast CancerThe Intergroup Exemestane Study 031 (IES) was a randomized, <BR>double-blind, multicenter, multinational study comparing exemestane (25 mg/day) <BR>versus tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast <BR>cancer. Patients who remained disease-free after receiving adjuvant tamoxifen <BR>therapy for 2 to 3 years were randomized to receive 3 to 2 years of AROMASIN or <BR>tamoxifen to complete a total of 5 years of hormonal therapy.<BR>                  The primary objective of the study was to determine whether, in terms of <BR>disease-free survival, it was more effective to switch to AROMASIN rather than <BR>continuing tamoxifen therapy for the remainder of five years. Disease-free <BR>survival was defined as the time from randomization to time of local or distant <BR>recurrence of breast cancer, contralateral invasive breast cancer, or death from <BR>any cause. <BR>                  The secondary objectives were to compare the two regimens in terms of overall <BR>survival and long-term tolerability. Time to contralateral invasive breast <BR>cancer and distant recurrence-free survival were also evaluated.<BR>                  A total of 4724 patients in the intent-to-treat (ITT) analysis were <BR>randomized to AROMASIN (exemestane tablets) 25 mg once daily (N = 2352) or to <BR>continue to receive tamoxifen once daily at the same dose received before <BR>randomization (N = 2372). Demographics and baseline tumor characteristics are <BR>presented in Table 1. Prior breast cancer therapy is summarized in Table 2.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="i0d6d005b-befb-47f5-83d0-cd2c14872dd0" width="75%"><BR>                     <caption>Table 1. Demographic and Baseline Tumor Characteristics from the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)</caption><BR>                     <tbody><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Parameter</content><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Exemestane</content><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Tamoxifen</content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Age (years):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">(N = 2352)</content><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">(N = 2372)</content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Median age (range)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br/><BR>                           </td><BR>                           <td>63.0 (38.0 - 96.0)<br/><BR>                           </td><BR>                           <td>63.0 (31.0 - 90.0)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Race, n (%):<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Caucasian<br/><BR>                           </td><BR>                           <td>2315 (98.4)<br/><BR>                           </td><BR>                           <td>2333 (98.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Hispanic<br/><BR>                           </td><BR>                           <td>13 (0.6)<br/><BR>                           </td><BR>                           <td>13 (0.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Asian<br/><BR>                           </td><BR>                           <td>10 (0.4)<br/><BR>                           </td><BR>                           <td>9 (0.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Black<br/><BR>                           </td><BR>                           <td>7 (0.3)<br/><BR>                           </td><BR>                           <td>10 (0.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Other/not reported<br/><BR>                           </td><BR>                           <td>7 (0.3)<br/><BR>                           </td><BR>                           <td>7 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Nodal status, n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Negative<br/><BR>                           </td><BR>                           <td>1217 (51.7)<br/><BR>                           </td><BR>                           <td>1228 (51.8)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Positive<br/><BR>                           </td><BR>                           <td>1051 (44.7)<br/><BR>                           </td><BR>                           <td>1044 (44.0)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>&#160;&#160; 1-3 Positive nodes<br/><BR>                           </td><BR>                           <td>721 (30.7)<br/><BR>                           </td><BR>                           <td>708 (29.8)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>&#160;&#160; 4-9 Positive nodes<br/><BR>                           </td><BR>                           <td>239 (10.2)<br/><BR>                           </td><BR>                           <td>244 (10.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>&#160;&#160; Greater than 9 Positive nodes<br/><BR>                           </td><BR>                           <td>88 (3.7)<br/><BR>                           </td><BR>                           <td>86 (3.6)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>&#160;&#160; Not reported<br/><BR>                           </td><BR>                           <td>3 (0.1)<br/><BR>                           </td><BR>                           <td>6 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Unknown or missing<br/><BR>                           </td><BR>                           <td>84 (3.6)<br/><BR>                           </td><BR>                           <td>100 (4.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Histologic type, n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Infiltrating ductal<br/><BR>                           </td><BR>                           <td>1777 (75.6)<br/><BR>                           </td><BR>                           <td>1830 (77.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Infiltrating lobular<br/><BR>                           </td><BR>                           <td>341 (14.5)<br/><BR>                           </td><BR>                           <td>321 (13.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Other<br/><BR>                           </td><BR>                           <td>231 (9.8)<br/><BR>                           </td><BR>                           <td>213 (9.0)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Unknown or missing<br/><BR>                           </td><BR>                           <td>3 (0.1)<br/><BR>                           </td><BR>                           <td>8 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Receptor status (*), n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>ER and PgR Positive<br/><BR>                           </td><BR>                           <td>1331 (56.6)<br/><BR>                           </td><BR>                           <td>1319 (55.6)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>ER Positive and PgR Negative/Unknown<br/><BR>                           </td><BR>                           <td>677 (28.8)<br/><BR>                           </td><BR>                           <td>692 (29.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>ER Unknown and PgR Positive (**)/Unknown<br/><BR>                           </td><BR>                           <td>288 (12.2)<br/><BR>                           </td><BR>                           <td>291 (12.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>ER Negative and PgR Positive<br/><BR>                           </td><BR>                           <td>6 (0.3)<br/><BR>                           </td><BR>                           <td>7 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>ER Negative and PgR Negative/Unknown (none positive)<br/><BR>                           </td><BR>                           <td>48 (2.0)<br/><BR>                           </td><BR>                           <td>58 (2.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Missing<br/><BR>                           </td><BR>                           <td>2 (0.1)<br/><BR>                           </td><BR>                           <td>5 (0.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Tumor Size, n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Less than or equal to 0.5 cm<br/><BR>                           </td><BR>                           <td>58 (2.5)<br/><BR>                           </td><BR>                           <td>46 (1.9)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Greater than 0.5 - 1.0 cm<br/><BR>                           </td><BR>                           <td>315 (13.4)<br/><BR>                           </td><BR>                           <td>302 (12.7)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Greater than 1.0 - 2 cm<br/><BR>                           </td><BR>                           <td>1031 (43.8)<br/><BR>                           </td><BR>                           <td>1033 (43.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Greater than 2.0 - 5.0 cm<br/><BR>                           </td><BR>                           <td>833 (35.4)<br/><BR>                           </td><BR>                           <td>883 (37.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Greater than 5.0 cm<br/><BR>                           </td><BR>                           <td>62 (2.6)<br/><BR>                           </td><BR>                           <td>59 (2.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Not reported<br/><BR>                           </td><BR>                           <td>53 (2.3)<br/><BR>                           </td><BR>                           <td>49 (2.1)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Tumor Grade, n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>G1<br/><BR>                           </td><BR>                           <td>397 (16.9)<br/><BR>                           </td><BR>                           <td>393 (16.6)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>G2<br/><BR>                           </td><BR>                           <td>977 (41.5)<br/><BR>                           </td><BR>                           <td>1007 (42.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>G3<br/><BR>                           </td><BR>                           <td>454 (19.3)<br/><BR>                           </td><BR>                           <td>428 (18.0)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>G4<br/>Unknown/Not Assessed/Not reported<br/><BR>                           </td><BR>                           <td>23 (1.0<br/>501 (21.3)<br/><BR>                           </td><BR>                           <td>19 (0.8)<br/>525 (22.1)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR><BR>(*)    Results for receptor status include the results of the <BR>post-randomization testing of specimens from subjects for whom receptor status <BR>was unknown at randomization.<BR><BR>                  (**)  Only one subject in the exemestane group had unknown ER <BR>status and positive PgR status.<BR><BR>                     <BR><BR>                  <BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="i19782b27-b2c1-4585-8793-caae5a5e554d" width="75%"><BR>                     <caption>Table 2. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)</caption><BR>                     <tbody><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Parameter</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Exemestane<br/>(N = 2352)<br/><BR>                              </content><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Tamoxifen<br/>(N = 2372)<br/><BR>                              </content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Type of surgery, n (%):</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Mastectomy<br/><BR>                           </td><BR>                           <td>1232 (52.4)<br/><BR>                           </td><BR>                           <td>1242 (52.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Breast-conserving<br/><BR>                           </td><BR>                           <td>1116 (47.4)<br/><BR>                           </td><BR>                           <td>1123 (47.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Unknown or missing<br/><BR>                           </td><BR>                           <td>4 (0.2)<br/><BR>                           </td><BR>                           <td>7 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Radiotherapy to the breast, n (%):</content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Yes<br/><BR>                           </td><BR>                           <td>1524 (64.8)<br/><BR>                           </td><BR>                           <td>1523 (64.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>No<br/><BR>                           </td><BR>                           <td>824 (35.5)<br/><BR>                           </td><BR>                           <td>843 (35.5)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Not reported<br/><BR>                           </td><BR>                           <td>4 (0.2)<br/><BR>                           </td><BR>                           <td>6 (0.3)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Prior therapy, n (%):</content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Chemotherapy<br/><BR>                           </td><BR>                           <td>774 (32.9)<br/><BR>                           </td><BR>                           <td>769 (32.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Hormone replacement therapy<br/><BR>                           </td><BR>                           <td>567 (24.1)<br/><BR>                           </td><BR>                           <td>561 (23.7)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Bisphosphonates<br/><BR>                           </td><BR>                           <td>43 (1.8)<br/><BR>                           </td><BR>                           <td>34 (1.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Duration of tamoxifen therapy at randomization </content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">months:</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Median (range)<br/><BR>                           </td><BR>                           <td>28.5 (15.8 - 52.2)<br/><BR>                           </td><BR>                           <td>28.4 (15.6 - 63.0)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Tamoxifen dose, n (%):</content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>20 mg<br/><BR>                           </td><BR>                           <td>2270 (96.5)<br/><BR>                           </td><BR>                           <td>2287 (96.4)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>30 mg (*)<br/><BR>                           </td><BR>                           <td>78 (3.3)<br/><BR>                           </td><BR>                           <td>75 (3.2)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Not reported<br/><BR>                           </td><BR>                           <td>4 (0.2)<br/><BR>                           </td><BR>                           <td>10 (0.4)<br/><BR>                           </td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR><BR>(*)   The 30 mg dose was used only in Denmark, where this dose was <BR>the standard of care.<BR><BR>                     <BR><BR>                  After a median duration of therapy of 27 months and with a median follow-up of <BR>34.5 months, 520 events were reported, 213 in the AROMASIN group and 307 in the <BR>tamoxifen group (Table 3).<BR><BR>                  <BR><BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="i3d354670-3471-4c5f-8d6f-379cc5dde1b9" width="60%"><BR>                     <caption>Table 3. Primary Endpoint Events (ITT Population)</caption><BR>                     <tbody><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Event</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold"><BR>                                 <br/><BR>                              </content><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">First Event</content><BR>                              <br/><BR>                              <content styleCode="bold">N (%)</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Exemestane<br/>(N = 2352)<br/><BR>                              </content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">Tamoxifen<br/>(N = 2372)<br/><BR>                              </content><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Loco-regional recurrence<br/><BR>                           </td><BR>                           <td>34 (1.4)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>45 (1.90)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Distant recurrence<br/><BR>                           </td><BR>                           <td>126 (5.36)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>183 (7.72)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Second primary - contralateral breast cancer<br/><BR>                           </td><BR>                           <td>7 (0.30)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>25 (1.05)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Death - breast cancer<br/><BR>                           </td><BR>                           <td>1 (0.04<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>6 (0.25)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Death - other reason<br/><BR>                           </td><BR>                           <td>41 (1.74)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>43 (1.81)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Death - missing/unknown<br/><BR>                           </td><BR>                           <td>3 (0.13)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>5 (0.21)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Ipsilateral breast cancer<br/><BR>                           </td><BR>                           <td>1 (0.04)<br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>0<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">Total number of events</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">213 (9.06)</content><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <content styleCode="bold">307 (12.94)</content><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                     </tbody><BR>                  </table>Disease-free survival in the intent-to-treat population was statistically <BR>significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = <BR>0.00003, Table 4, Figure 1] in the AROMASIN arm compared to the tamoxifen arm. <BR>In the hormone receptor-positive subpopulation representing about 85% of the <BR>trial patients, disease-free survival was also statistically significantly <BR>improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the AROMASIN arm <BR>compared to the tamoxifen arm. Consistent results were observed in the subgroups <BR>of patients with node negative or positive disease, and patients who had or had <BR>not received prior chemotherapy. Overall survival was not significantly <BR>different in the two groups, with 116 deaths occurring in the AROMASIN group and <BR>137 in the tamoxifen group.<BR><BR><BR><BR><BR>                  <BR><BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="i902a6dc4-7a7f-4ade-80d5-628bcd17af84" width="60%"><BR>                     <caption>Table 4. Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer</caption><BR>                     <tbody><BR>                        <tr><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td>Hazard Ratio<br/><BR>                           </td><BR>                           <td>p-value<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">ITT Population</content><BR>                              <br/><BR>                           </td><BR>                           <td>(95% CI)<br/><BR>                           </td><BR>                           <td>(log-rank test)<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Disease free survival </td><BR>                           <td>0.69 (0.58 - 0.82)<br/><BR>                           </td><BR>                           <td>0.00003<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Time to contralateral breast cancer</td><BR>                           <td>0.32 (0.15 - 0.72)<br/><BR>                           </td><BR>                           <td>0.00340<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Distant recurrence free survival</td><BR>                           <td>0.74 (0.62 - 0.90)<br/><BR>                           </td><BR>                           <td>0.00207<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Overall survival </td><BR>                           <td>0.86 (0.67 - 1.10)<br/><BR>                           </td><BR>                           <td>0.22962<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td><BR>                              <content styleCode="bold">ER and/or PgR positive</content><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                           <td><BR>                              <br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Disease free survival </td><BR>                           <td>0.65 (0.53 - 0.79)<br/><BR>                           </td><BR>                           <td>0.00001<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Time to contralateral breast cancer</td><BR>                           <td>0.22 (0.08 - 0.57)<br/><BR>                           </td><BR>                           <td>0.00069<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Distant recurrence free survival</td><BR>                           <td>0.73 (0.59 - 0.90)<br/><BR>                           </td><BR>                           <td>0.00367<br/><BR>                           </td><BR>                        </tr><BR>                        <tr><BR>                           <td>Overall survival </td><BR>                           <td>0.88 (0.67 - 1.17)<br/><BR>                           </td><BR>                           <td>0.37460<br/><BR>                           </td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR><BR><BR>                  Figure 1. Disease Free Survival in the IES Study of <BR>Postmenopausal Women with Early Breast Cancer (ITT Population)<BR><BR>                  <BR>                  <BR>                  <BR><BR>                  <BR><BR>               <BR>               <BR>               <BR>                  <BR>                     image of Figure 1.Disease Free Survival graph<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>